World J Gastroenterol. 2011 Dec 28;17(48):5231-9. doi: 10.3748/wjg.v17.i48.5231.
In spite of the well-established understanding of the phenotypic lesions occurring in the shift from native epithelia to invasive (adeno) carcinoma, the molecular typing of the precancerous changes in the gastrointestinal tract remains unreliable. In recent years, no biomarkers have aroused as much interest as the miRNAs, a class of non-coding RNA molecules that function as endogenous silencers of numerous target genes. Aberrant miRNA expression is a hallmark of human disease, including cancer. Unlike most mRNAs, miRNAs are both long-living in vivo and very stable in vitro. Such characteristics allow their testing in paraffin-embedded tissue samples, which is essential in the biological profiling of small (phenotypically characterized) preneoplastic lesions of the gastrointestinal tract (as well as in other fields of human pathology). The upcoming challenge lies in the reliable identification of disease-specific targets of dysregulated miRNAs, to enable miRNA testing in the clinical management of the secondary prevention of gastrointestinal cancer.
尽管人们对从固有上皮到侵袭性(腺)癌发生的表型病变有了明确的认识,但胃肠道癌前病变的分子分型仍然不可靠。近年来,没有任何生物标志物像 miRNA 那样引起人们的兴趣,miRNA 是一类非编码 RNA 分子,作为许多靶基因的内源性沉默子发挥作用。miRNA 表达异常是人类疾病的标志,包括癌症。与大多数 mRNA 不同,miRNA 在体内寿命长,在体外非常稳定。这些特征使其能够在石蜡包埋组织样本中进行检测,这对于胃肠道小(表型特征明确)癌前病变的生物学特征分析(以及人类病理学的其他领域)至关重要。即将面临的挑战在于可靠地识别失调 miRNA 的疾病特异性靶标,从而能够在胃肠道癌二级预防的临床管理中进行 miRNA 检测。